These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 8604621)
81. Controlled continuous systemic heparinization increases success rate of artery-only anastomosis replantation in single distal digit amputation: A retrospective cohort study. Lee JY; Kim HS; Heo ST; Kwon H; Jung SN Medicine (Baltimore); 2016 Jun; 95(26):e3979. PubMed ID: 27367997 [TBL] [Abstract][Full Text] [Related]
82. Case studies in therapeutics: warfarin resistance and inefficacy in a man with recurrent thromboembolism, and anticoagulant-associated priapism. Routledge PA; Shetty HG; White JP; Collins P Br J Clin Pharmacol; 1998 Oct; 46(4):343-6. PubMed ID: 9803981 [TBL] [Abstract][Full Text] [Related]
83. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Granger CB; Miller JM; Bovill EG; Gruber A; Tracy RP; Krucoff MW; Green C; Berrios E; Harrington RA; Ohman EM Circulation; 1995 Apr; 91(7):1929-35. PubMed ID: 7895349 [TBL] [Abstract][Full Text] [Related]
84. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris. Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862 [TBL] [Abstract][Full Text] [Related]
85. Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential. Becker RC; Spencer FA; Li Y; Ball SP; Ma Y; Hurley T; Hebert J J Am Coll Cardiol; 1999 Oct; 34(4):1020-7. PubMed ID: 10520784 [TBL] [Abstract][Full Text] [Related]
86. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors. Lepor NE Rev Cardiovasc Med; 2007; 8 Suppl 3():S9-17. PubMed ID: 17917621 [TBL] [Abstract][Full Text] [Related]
87. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Becker RC; Cannon CP; Tracy RP; Thompson B; Bovill EG; Desvigne-Nickens P; Randall AM; Knatternud G; Braunwald E Am Heart J; 1996 Mar; 131(3):421-33. PubMed ID: 8604620 [TBL] [Abstract][Full Text] [Related]
88. Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin. Ramana RK; Lewis BE Vasc Health Risk Manag; 2008; 4(3):493-505. PubMed ID: 18827868 [TBL] [Abstract][Full Text] [Related]
89. Integration of anticoagulation, thrombolysis and coronary angioplasty for unstable angina pectoris. Topol EJ Am J Cardiol; 1991 Sep; 68(7):136B-141B. PubMed ID: 1892061 [TBL] [Abstract][Full Text] [Related]
90. Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Carswell CI; Plosker GL Drugs; 2002; 62(5):841-70. PubMed ID: 11929334 [TBL] [Abstract][Full Text] [Related]
91. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123 [TBL] [Abstract][Full Text] [Related]
92. Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. Smith AJ; Holt RE; Fitzpatrick JB; Palacios IF; Gold HK; Werner W; Bovill EG; Fuster V; Jang IK Am Heart J; 1996 Mar; 131(3):434-9. PubMed ID: 8604621 [TBL] [Abstract][Full Text] [Related]